Document Detail


Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
MedLine Citation:
PMID:  17008095     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Randomised phase III trials are the ideal setting for prospective collection of economic and health related quality of life (HRQL) data. Many studies combine prospective clinical data with economic assumptions or data collected in separate costing studies. To extrapolate the trial outcomes to lifelong consequences, modelling approaches are often used. Also, in situations where no randomised trial data are available, modelling approaches are often applied. In this paper some methodological and practical issues are described. The aim of the economic evaluations is to support decision-making. As many new promising anti cancer drugs are forthcoming, the questions of how decision-makers will use the results of the economic evaluations and how patients can optimally benefit from these new drugs arise.
Authors:
Carin A Uyl-de Groot
Related Documents :
4019705 - Determining the duration of comparative clinical trials while allowing for cure.
20473185 - Bayesian meta-analyses for comparative effectiveness and informing coverage decisions.
18999175 - Clinical trials in silico: rigorous assessment of treatment effect using electronic hea...
9160485 - Power considerations for clinical trials using multivariate time-to-event data.
12413145 - Stress assessment by means of questionnaires.
23071215 - Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population.
Publication Detail:
Type:  Journal Article; Review     Date:  2006-09-27
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  42     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-07     Completed Date:  2007-02-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  2862-6     Citation Subset:  IM    
Affiliation:
Institute for Medical Technology Assessment, Erasmus MC, University Medical Centre, PO Box 1700, 3000 DR Rotterdam, The Netherlands. c.uyl@erasmusmc.nl <c.uyl@erasmusmc.nl>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / economics
Cost-Benefit Analysis
Decision Making
Humans
Neoplasms / economics*,  therapy
Randomized Controlled Trials as Topic
Risk Assessment
Sample Size
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Health technology assessment in cancer: a personal view from public health.
Next Document:  Evaluation of a upflow anaerobic sludge blanket reactor with partial recirculation of effluent used ...